Results

RDF/XMLNTriplesTurtleShow queryShare
SubjectPredicateObject
http://purl.uniprot.org/SHA-384/1B1A028457E7C408B11D536B04108322D41683CF5C74D0D930247E9D4F00CCDC3D09DB1206B4535E3B3F7B310B142E54http://www.w3.org/1999/02/22-rdf-syntax-ns#typehttp://purl.uniprot.org/core/Annotation
http://purl.uniprot.org/SHA-384/1B1A028457E7C408B11D536B04108322D41683CF5C74D0D930247E9D4F00CCDC3D09DB1206B4535E3B3F7B310B142E54http://www.w3.org/2000/01/rdf-schema#comment"This is the first report showing that high bone marrow LRP expression predicts significant favorable therapeutic outcome. Peripheral blood LRP expression as well as marrow and blood MDR1 and MRP2 expression have no predictive value in AML patients treated with standard dose cytarabine and daunorubicin 3+7 regimen."xsd:string
http://purl.uniprot.org/uniprot/#_A534750837EDD2A1787C87832CDFE2559D8017A3C8290FE375C55B36BBFE0BE26BF4057E76B845413C05597B0457B6A8http://www.w3.org/1999/02/22-rdf-syntax-ns#subjecthttp://purl.uniprot.org/SHA-384/1B1A028457E7C408B11D536B04108322D41683CF5C74D0D930247E9D4F00CCDC3D09DB1206B4535E3B3F7B310B142E54
http://purl.uniprot.org/uniprot/Q14764http://purl.uniprot.org/core/mappedAnnotationhttp://purl.uniprot.org/SHA-384/1B1A028457E7C408B11D536B04108322D41683CF5C74D0D930247E9D4F00CCDC3D09DB1206B4535E3B3F7B310B142E54
http://purl.uniprot.org/uniprot/#_Q14764-mappedCitation-30674943http://purl.uniprot.org/core/mappedAnnotationhttp://purl.uniprot.org/SHA-384/1B1A028457E7C408B11D536B04108322D41683CF5C74D0D930247E9D4F00CCDC3D09DB1206B4535E3B3F7B310B142E54